

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

CSPC PHARMACEUTICAL GROUP LIMITED,  
CSPC OUYI PHARMACEUTICAL CO., LTD., AND  
CONJUPRO BIOTHERAPEUTICS, INC.,  
Petitioners,

v.

IPSEN BIOPHARM LTD.,  
Patent Owner.

---

Case No. IPR2025-00505  
Patent No. 11,344,552

---

**PETITIONERS' MOTION TO SEAL**

Pursuant to 37 C.F.R. §§ 42.14 and 42.54, Petitioners respectfully submit this Motion to Seal Petitioner's Reply to Patent Owner's Response ("the Reply") and a confidential exhibit concurrently filed therewith.

**I. Good Cause Exists for Sealing the Exhibit.**

Petitioners move to seal Exhibit 1210, which is the deposition transcript of Patent Owner's Expert, Dr. Paul Oberstein. Patent Owner has designated portions of the transcript as confidential. While the parties disagree about the scope of information that is confidential, the parties do agree that Exhibit 1210 does contain confidential financial information for Dr. Oberstein that is used in the Reply. Therefore, Petitioner also moves to seal the Reply.

Petitioners are also filing redacted versions of Exhibit 1210 and the Reply, publicly, and non-redacted versions, under seal. The parties request that the Board maintain the non-redacted exhibit as under seal and the redacted exhibit as the public version.

**II. Certification of Non-Public Status.**

Petitioners have identified portions of the Patent Owner's redactions that it believes are publicly available but Patent Owner is still evaluating Petitioner's position. Petitioner is unaware of any public source of information as to the specific financial information redacted in Exhibit 1210.

**III. Certification of Conference Between the Parties Pursuant to 37 C.F.R. § 42.54(a).**

The undersigned counsel for Petitioners certifies that they have in good faith met and conferred with counsel for Patent Owner and have agreed that Exhibit 1210 and the Reply should be filed under seal at this time.

**IV. Conclusion**

In light of the good cause identified herein, Petitioners respectfully request that the Board grant its Motion to Seal.

Dated: February 11, 2026

By: /s/ Lukas D. Toft  
Lukas D. Toft (Reg. No. 75,311)  
FOX ROTHSCHILD LLP  
33 South 6th Street, Suite 3600  
Minneapolis, MN 55402  
Telephone: (612) 607-7336  
Facsimile: (612) 607-7100  
ltoft@foxrothschild.com

Joe Chen, Ph.D. (Reg. No. 70,066)  
FOX ROTHSCHILD LLP  
212 Carnegie Center, Suite 400  
Princeton, NJ 08540  
Telephone: (609) 844-3024  
Facsimile: (609) 896-1469  
joechen@foxrothschild.com

Howard S. Suh (*pro hac vice*)  
Fox Rothschild LLP  
101 Park Avenue, 17th Floor  
New York, NY 10178  
Telephone: (212) 878-7914  
Facsimile: (212) 692-0940  
hsuh@foxrothschild.com

**Attorneys for CSPC Pharmaceutical Group  
Limited, CSPC Ouyi Pharmaceutical Co.,  
Ltd., and Conjurpro Biotherapeutics, Inc.**

**CERTIFICATE OF SERVICE**

Pursuant to 37 CFR § 42.6(e), the undersigned hereby certifies that on February 11, 2026, the foregoing Petitioners' Motion to Seal was served via electronic mail, as authorized by Patent Owner, at the following email addresses:

Lead Counsel

James M. Glass, Reg. No. 46,729  
jimglass@quinnemanuel.com  
michaellabas@quinnemanuel.com

Backup Counsel

Angus Chen, Reg. No. 73,566  
anguschen@quinnemanuel.com

Quincy Lu, Reg. No. 76,954  
quincylu@quinnemanuel.com

Catherine Mattes, Reg. No. 68,346  
catherinemattes@quinnemanuel.com

Elizabeth Murphy (*pro hac vice* forthcoming)  
elizabethmurphy@quinnemanuel.com

Ross Misskelley (*pro hac vice* forthcoming)  
rossmisskelley@quinnemanuel.com

Dated: February 11, 2026

/s/ Lukas D. Toft

Lukas D. Toft (Reg. No. 75,311)

Joe Chen, Ph.D. (Reg. No. 70,066)

Howard S. Suh (*pro hac vice*)

Counsel for Petitioners

**Attorneys for CSPC Pharmaceutical Group  
Limited, CSPC Ouyi Pharmaceutical Co.,  
Ltd., and Conjurpro Biotherapeutics, Inc.**